We are actively reviewing claims involving GLP-1 drugs such as Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro , including cases involving: If you or a loved one experienced serious health problems after taking a GLP-1 medication, you may be entitled to financial compensation
UK product information includes warnings about thyroid C-cell tumours observed in rodent studies, though this is not a formal contraindication in the UK as it is in some other countries
The services may also get their prescriptions from pharmacies that do not have strict protocols or standards, leading to improper dosing and/or impurities
Gastrointestinal side effects, including constipation, nausea, and altered bowel habits, occur frequently with these medicines
Iron: especially critical for women Iron deficiency anemia is a real risk during GLP-1 therapy, particularly for premenopausal women who lose iron monthly through menstruation
Key Highlights: 48 PSGs for products with no approved ANDAs (25 complex products) 39 PSGs for complex products (6 new, 33 revised) Therapies for COPD, opioid overdose, type 2 diabetes, major depressive disorder, and more Notable PSGs: Ensifentrine inhalation suspension (COPD, RLD: OHTUVAYRE) Naloxone hydrochloride nasal spray (Opioid overdose, RLD: REZENOPY) Semaglutide oral tablet (Type 2 diabetes, RLD: RYBELSUS) Trazodone hydrochloride ER oral tablet (MDD, RLD: OLEPTRO) Link : By publishing PSGs, FDA continues to promote innovation in generic development while advancing public health and patient access to cost-effective medicines